Barry Callebaut AG (0QO7)
London Exchange · UK · prices in GBP · close of 22 Oct 2026
Key indicators
| Last close | GBP 1,154.50 |
|---|---|
| 52-week range | 991.00 – 1,534.00 |
| Return, 1 month / 3 months | +0.7% / +2.3% |
| Return, 1 year / 3 years | −5.2% / −14.9% |
| Trend | Below its 200-day average |
| RSI (14) | 60 |
| Volatility (1 year) | 36.1% |
| Worst drawdown (1 year) | -32.0% |
| Average daily value traded | 2.17M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Barry Callebaut is a cocoa and chocolate manufacturer based in Switzerland. It makes chocolate and cocoa products for food companies, confectioners and other industrial customers, supplying ingredients such as cocoa powder, cocoa butter and chocolate coatings. The company also provides gourmet and decoration products for chefs and artisans. Its customers are mainly businesses that use chocolate and cocoa as inputs for their own products, rather than individual shoppers.
The shares are listed on the London Exchange in UK under the code 0QO7, and the price on this page is in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Barry Callebaut AG (0QO7) trades on the London Exchange in UK. It last closed at GBP 1,154.50 on 22 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 2,205 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 5.2% and over the last three months it rose 2.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 33 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.5% | ||
| From 52-week high | -24.2% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.3% | ||
| 6-month return | 8.5% | ||
| 12-month return, skipping the last month | -5.9% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.0% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.17M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +3.1% |
|---|---|
| 1 month | +0.7% |
| 3 months | +2.3% |
| 6 months | +8.5% |
| 1 year | −5.2% |
| 3 years | −14.9% |
| 5 years | −45.2% |
Signals
| 50-day / 200-day average | 1,107.32 / 1,208.65 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 44.78 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Jan 2026 | GBX 0.2900 |
| 7 Jan 2025 | GBX 0.2900 |
| 8 Jan 2024 | GBX 0.2900 |
| 9 Jan 2023 | GBX 0.2800 |
| 4 Jan 2022 | GBX 0.2800 |
| 5 Jan 2021 | GBX 0.2200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.